Trastuzumab Biosimilars Industry Revenue to Reach $24.48 Billion by 2030 with CAGR of 28.9% (2026-2030)

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Growth Potential of the Traumatic Brain Injury Biomarkers Market in the Next Decade?
The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2025 to $8.86 billion in 2026 at a compound annual growth rate (CAGR) of 28.5%. The growth in the historic period can be attributed to high incidence of HER2 positive breast cancer, loss of trastuzumab patent exclusivity, rising oncology drug costs, regulatory biosimilar pathways, hospital oncology adoption.

The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $24.48 billion in 2030 at a compound annual growth rate (CAGR) of 28.9%. The growth in the forecast period can be attributed to increasing cancer prevalence, expansion into gastric cancer indications, favorable reimbursement for biosimilars, growing physician confidence, rising healthcare cost containment efforts. Major trends in the forecast period include rapid uptake of oncology biosimilars, improved access to HER2 targeted therapies, price competition in breast cancer treatment, expansion of hospital oncology use, growing acceptance of biosimilar switching.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Drivers Are Positively Impacting the Trastuzumab Biosimilars Market?
The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilars market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 297,790 new cases of invasive breast cancer will be diagnosed in women in 2023, and about 43,700 women will die from breast cancer in the same year. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that help save money when compared to expensive medicines, thereby driving the trastuzumab biosimilars market.

What Segment Defines the Trastuzumab Biosimilars Market?
The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Are the Major Trends Impacting the Trastuzumab Biosimilars Market?
Major players are continuously focusing on launching new products in untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives, such as new product development, partnerships, and geographical and product portfolio expansion, to maintain their competitive position in the market and better serve the needs of the customers. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab) for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is prescribed for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are generally aggressive but respond effectively to targeted therapies. HERCESSI works by binding to the HER2 receptor, inhibiting its activity and thereby slowing down the replication of cancer cells.

Which Major Companies Are Operating in the Trastuzumab Biosimilars Market?
Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited

Get the full trastuzumab biosimilars market report here:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Regions Offer the Highest Potential for Trastuzumab Biosimilars Market Expansion?
North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn